Position in NVO
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$54,651
-$23,626 QoQ
Shares Held
1,140
-46.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#1,117
of 1,348 holders
Holding Since
Mar 2020
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Derivatives in NVO
reported options exposure · as of Dec 31, 2025CallValue
$21,878
CallShares
430
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FNY Investment Advisers, LLC holds $3,050,095 across 6 Drug Manufacturers - General names. NVO ranks #4 (1.8% of the industry book) .
All Filings in NVO
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $54,651 | 1,140 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $78,277 | 2,130 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $21,878 | 430 | Call | Sole | 2026-01-16 | |
| 2025-12-31 | $106,848 | 2,100 | Shares | Sole | 2026-01-16 | |
| 2025-03-31 | $623,015 | 8,972 | Shares | Sole | 2025-04-17 | |
| 2023-09-30 | $272,820 | 3,000 | Shares | Defined | 2023-10-10 | |
| 2022-09-30 | $3,985,200 | 40,000 | Shares | Sole | 2022-10-19 | |
| 2022-09-30 | $7,671 | 77 | Call | Sole | 2022-10-19 | |
| 2020-12-31 | $1,320,165 | 18,900 | Shares | Sole | 2021-01-19 | |
| 2020-09-30 | $1,270,569 | 18,300 | Shares | Sole | 2020-10-09 | |
| 2020-06-30 | $412,524 | 6,300 | Shares | Sole | 2020-07-10 | |
| 2020-03-31 | $301,000 | 5,000 | Shares | Sole | 2020-04-09 | |
| No filing history on record for this holder in this stock. | ||||||